Study | Study description | Number of volunteers | Mean (IQR) age years | Sex balance n (%) | Inoculation months for study (number of volunteers) | Carriage rate % | Mean (IQR) inoculation dose CFU |
11/NW/0592 | To establish >40% carriage using Spn6B and Spn23F; participants inoculated with Spn6B included in this analysis (started 2011) | 86 | 23 (22–34) | 49 (57.0) female | January (20) March (4) June (6) July (4) September (8) October (14) November (22) December (8) | 45.3 | 89 929 (33 999–104 500) |
14/NW/1460 (Study 1) | To define the effect of LAIV on EHPC; study control group included in this analysis (started 2016) | 62 | 21 (19–22) | 32 (51.6) female | January (19) February (15) March (6) November (22) | 38.7 | 75 575 (70 166–81 499) |
14/NW/1460 (Study 2) | As study 1 | 163 | 21 (19–22) | 89 (54.6) female | January (35) February (42) March (22) October (30) November (34) | 49.7 | 81 249 77 833–85 333) |
15/NW/0146 | Pilot study of repeated mucosal sampling on EHPC (started 2015) | 18 | 28 (22–34) | 12 (66.7) female | July (15) August (3) | 38.9 | 80 823 (77 166–84 333) |
12/NW/0873 | To evaluate the effect of PCV on EHPC compared to hepatitis A vaccine; study control group included in this analysis (started 2013) | 45 | 23 (19–23) | 28 (62.2) female | February (3) March (18) May (9) October (1) November (14) | 44.4 | 82 938 (77 833–88 583) |
Pooled data | |||||||
All (pooled) | 374 | 22 (19–22) | 210 (56.2) female | January (74) February (60) March (50) May (9) June (6) July (19) August (3) September (8) October (45) November (92) December (8) | 45.7 | 82 502 (74 333–85 333) |
Spn6B: serotype 6B pneumococcus; Spn23F: serotype 23F pneumococcus; +LAIV: live attenuated influenza vaccine; EHPC: experimental human pneumococcal carriage; PCV: pneumococcal conjugate vaccine.